BR0110492A - Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto - Google Patents
Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do compostoInfo
- Publication number
- BR0110492A BR0110492A BR0110492-6A BR0110492A BR0110492A BR 0110492 A BR0110492 A BR 0110492A BR 0110492 A BR0110492 A BR 0110492A BR 0110492 A BR0110492 A BR 0110492A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- preparing
- diabetes
- useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000012190 activator Substances 0.000 abstract 1
- 150000001469 hydantoins Chemical class 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE ESSE COMPOSTO, PROCESSO PARA A PREPARAçãO DE COMPOSIçãO FARMACêUTICA, UTILIZAçãO DO COMPOSTO E PROCESSO PARA A PREPARAçãO DO COMPOSTO". Expõem-se compostos de hidantoína os quais são ativos como ativadores de glicoquinase para aumentarem a secreção de insulina que os torna de utilidade para tratamento de diabetes do tipo II.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20149800P | 2000-05-03 | 2000-05-03 | |
| PCT/EP2001/004555 WO2001083478A2 (en) | 2000-05-03 | 2001-04-23 | Hydantoin-containing glucokinase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0110492A true BR0110492A (pt) | 2003-04-08 |
Family
ID=22746054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0110492-6A BR0110492A (pt) | 2000-05-03 | 2001-04-23 | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6583288B2 (pt) |
| EP (1) | EP1280801B1 (pt) |
| JP (1) | JP3842131B2 (pt) |
| KR (1) | KR100505312B1 (pt) |
| CN (1) | CN1209361C (pt) |
| AR (1) | AR034253A1 (pt) |
| AT (1) | ATE304011T1 (pt) |
| AU (2) | AU5227001A (pt) |
| BR (1) | BR0110492A (pt) |
| CA (1) | CA2407428C (pt) |
| DE (1) | DE60113247T2 (pt) |
| DK (1) | DK1280801T3 (pt) |
| EC (1) | ECSP014055A (pt) |
| ES (1) | ES2248309T3 (pt) |
| MX (1) | MXPA02010746A (pt) |
| PE (1) | PE20011313A1 (pt) |
| PT (1) | PT1280801E (pt) |
| UY (1) | UY26689A1 (pt) |
| WO (1) | WO2001083478A2 (pt) |
| ZA (1) | ZA200208370B (pt) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110492A (pt) * | 2000-05-03 | 2003-04-08 | Hoffmann La Roche | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| RU2374236C2 (ru) | 2001-12-21 | 2009-11-27 | Ново Нордиск А/С | Амидные производные в качестве активаторов gk |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
| JP2006509774A (ja) | 2002-10-03 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | 2型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換(チアゾール−2−イル)−アミドまたはスルホンアミド |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) * | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| JP4621198B2 (ja) * | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ(シクロ)置換アミドグルコキナーゼ活性化化合物 |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| CN1910166B (zh) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| CN102516240A (zh) | 2004-01-06 | 2012-06-27 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| CN101098876A (zh) | 2004-04-02 | 2008-01-02 | 诺瓦提斯公司 | 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法 |
| US7750020B2 (en) | 2004-04-02 | 2010-07-06 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes |
| EP1781649B1 (en) * | 2004-08-17 | 2008-08-13 | F. Hoffmann-Roche AG | Substituted hydantoins |
| EP1793827B1 (en) * | 2004-09-09 | 2010-04-07 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirolactam cgrp receptor antagonists |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| US8003792B2 (en) | 2004-09-13 | 2011-08-23 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
| TW200621766A (en) * | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
| MX2008000294A (es) | 2005-07-08 | 2008-04-04 | Novo Nordisk As | Activadores de dicicloalquil urea glucocinasa. |
| BRPI0613570B8 (pt) | 2005-07-09 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| US7863329B2 (en) | 2005-11-17 | 2011-01-04 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| FR2894962B1 (fr) * | 2005-12-20 | 2008-03-14 | Pharmamens Sarl | Hydantoines a action insulinotropique |
| US7612212B2 (en) * | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US8008332B2 (en) | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
| US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
| EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| AU2008225613B2 (en) * | 2007-03-07 | 2012-06-14 | Kyorin Pharmaceutical Co., Ltd. | Glucokinase activator |
| AU2008226942A1 (en) * | 2007-03-12 | 2008-09-18 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirolactam CGRP receptor antagonists |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| CN101778839A (zh) * | 2007-08-16 | 2010-07-14 | 霍夫曼-拉罗奇有限公司 | 取代的乙内酰脲 |
| KR20100086503A (ko) | 2007-12-20 | 2010-07-30 | 에프. 호프만-라 로슈 아게 | Mek 키나아제 저해제로서의 치환된 히단토인 |
| US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| AR074619A1 (es) | 2008-04-28 | 2011-02-02 | Teijin Pharma Ltd | Derivados de ciclopentilacrilamida |
| UY31830A (es) | 2008-05-16 | 2010-01-05 | Takeda Pharmaceutical | Activadores de glucoquinasa |
| WO2010150280A1 (en) | 2009-06-22 | 2010-12-29 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
| US8835469B2 (en) | 2009-07-31 | 2014-09-16 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (GK) activators |
| CN105176930B (zh) | 2010-03-31 | 2021-05-04 | 斯克里普斯研究所 | 重编程细胞 |
| ES2671881B1 (es) * | 2016-11-11 | 2019-03-25 | Consejo Superior Investigacion | Procedimiento de obtencion de polimeros con grupos isocianato |
| CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202339A (en) * | 1987-08-28 | 1993-04-13 | Mochida Pharmaceutical Co., Ltd. | Hydantoin derivatives |
| US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| BR0110492A (pt) * | 2000-05-03 | 2003-04-08 | Hoffmann La Roche | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto |
-
2001
- 2001-04-23 BR BR0110492-6A patent/BR0110492A/pt not_active Application Discontinuation
- 2001-04-23 MX MXPA02010746A patent/MXPA02010746A/es active IP Right Grant
- 2001-04-23 CA CA002407428A patent/CA2407428C/en not_active Expired - Fee Related
- 2001-04-23 CN CNB018089135A patent/CN1209361C/zh not_active Expired - Fee Related
- 2001-04-23 PT PT01925563T patent/PT1280801E/pt unknown
- 2001-04-23 KR KR10-2002-7014735A patent/KR100505312B1/ko not_active Expired - Fee Related
- 2001-04-23 ES ES01925563T patent/ES2248309T3/es not_active Expired - Lifetime
- 2001-04-23 AU AU5227001A patent/AU5227001A/xx active Pending
- 2001-04-23 AU AU2001252270A patent/AU2001252270B2/en not_active Ceased
- 2001-04-23 WO PCT/EP2001/004555 patent/WO2001083478A2/en active IP Right Grant
- 2001-04-23 EP EP01925563A patent/EP1280801B1/en not_active Expired - Lifetime
- 2001-04-23 DE DE60113247T patent/DE60113247T2/de not_active Expired - Lifetime
- 2001-04-23 AT AT01925563T patent/ATE304011T1/de not_active IP Right Cessation
- 2001-04-23 DK DK01925563T patent/DK1280801T3/da active
- 2001-04-23 JP JP2001580906A patent/JP3842131B2/ja not_active Expired - Fee Related
- 2001-04-26 US US09/843,466 patent/US6583288B2/en not_active Expired - Fee Related
- 2001-04-30 AR ARP010102036A patent/AR034253A1/es unknown
- 2001-04-30 PE PE2001000389A patent/PE20011313A1/es not_active Application Discontinuation
- 2001-05-02 UY UY26689A patent/UY26689A1/es not_active Application Discontinuation
- 2001-05-03 EC EC2001004055A patent/ECSP014055A/es unknown
-
2002
- 2002-10-17 ZA ZA200208370A patent/ZA200208370B/en unknown
-
2003
- 2003-06-04 US US10/454,041 patent/US6784298B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030225286A1 (en) | 2003-12-04 |
| ECSP014055A (es) | 2002-01-25 |
| KR20020093120A (ko) | 2002-12-12 |
| US6784298B2 (en) | 2004-08-31 |
| DE60113247T2 (de) | 2006-06-22 |
| PT1280801E (pt) | 2005-11-30 |
| ZA200208370B (en) | 2004-01-26 |
| DE60113247D1 (de) | 2005-10-13 |
| JP2003531905A (ja) | 2003-10-28 |
| PE20011313A1 (es) | 2001-12-28 |
| AR034253A1 (es) | 2004-02-18 |
| US6583288B2 (en) | 2003-06-24 |
| WO2001083478A3 (en) | 2002-05-16 |
| JP3842131B2 (ja) | 2006-11-08 |
| US20010056191A1 (en) | 2001-12-27 |
| KR100505312B1 (ko) | 2005-08-04 |
| CN1209361C (zh) | 2005-07-06 |
| CA2407428C (en) | 2010-02-02 |
| DK1280801T3 (da) | 2006-01-23 |
| EP1280801B1 (en) | 2005-09-07 |
| UY26689A1 (es) | 2001-11-30 |
| AU5227001A (en) | 2001-11-12 |
| WO2001083478A2 (en) | 2001-11-08 |
| ATE304011T1 (de) | 2005-09-15 |
| CN1427838A (zh) | 2003-07-02 |
| CA2407428A1 (en) | 2001-11-08 |
| EP1280801A2 (en) | 2003-02-05 |
| ES2248309T3 (es) | 2006-03-16 |
| AU2001252270B2 (en) | 2005-12-15 |
| MXPA02010746A (es) | 2003-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0110492A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto | |
| BR0110573A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto | |
| BR0315047A (pt) | Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto | |
| BR0200782A (pt) | Compostos para o tratamento da isquemia | |
| SE0200979D0 (sv) | New compounds | |
| BR0209127A (pt) | compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| AR031828A2 (es) | Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia | |
| BRPI0415398A (pt) | composto, composição farmacêutica, processo para a preparação da mesma, uso de um composto, método de tratamento de cáncer, e, processo para preparação de um composto | |
| BR0309546A (pt) | Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii | |
| BR0317268A (pt) | Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| BR0207726A (pt) | Sais farmacêuticos | |
| TW200510375A (en) | New compounds | |
| BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
| BR0116169A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto. | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| YU69501A (sh) | Aktivatori glukokinaze | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| PA8503301A1 (es) | Compuestos para el tratamiento de la isquemia | |
| BR0108678A (pt) | Novos compostos | |
| BR0114321A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto | |
| BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
| BR0114092A (pt) | Guanididas de ácido cinámico substituìdas, processos para a sua preparação, sua aplicação como medicamento bem como o medicamento contendo as mesmas | |
| BR0311984A (pt) | Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação | |
| DE60035639D1 (de) | Hydroxydiphenyletherverbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |